Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy.
Cardiac disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Optimum management of cardiovascular disease can mean that patients with cancer can successfully receive therapies to treat their malignancy and can reduce morbidity and mortality due to cardiovascular disease in cancer survivors. The presence of cancer and cancer-related morbidities substantially complicates the management of cardiovascular disease in cancer patients. In this Review, we discuss management strategies for cardiovascular disease in patients with cancer, focusing on the prevention and treatment of congestive heart failure and myocardial infarction.
Khakoo
Aarif Y
AY
Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030-4095, USA. aykhakoo@mdanderson.org
Yeh
Edward T H
ET
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D009203:Myocardial Infarction / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy*; D017410:Practice Guidelines as Topic; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D013781:Texas / Q000453:epidemiology; D015912:Thrombolytic Therapy / Q000379:methods
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002316:Cardiotonic Agents